The epidemiology of high-risk prostate cancer

Current Opinion in Urology

Volumn 23, Issue 4, 2013, Pages 331-336

  Punnen, Sanoj ^a   Cooperberg, Matthew R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

epidemiology; high risk; prostate cancer; prostate neoplasms; risk assessment

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGE; ANDROGEN DEPRIVATION THERAPY; BRACHYTHERAPY; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; DIET; FAMILY HISTORY; GENETIC VARIABILITY; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HUMAN; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RACE; REVIEW; RISK ASSESSMENT; SOCIAL STATUS;

AGE FACTORS; EARLY DETECTION OF CANCER; HUMANS; INCIDENCE; KALLIKREINS; MALE; MASS SCREENING; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84880136854     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e328361d48e     Document Type: Review

References (39)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2013; 63:11-30.
2. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality in a randomized European Study. N Engl J Med 2009; 360:1320-1328.
3. Cooperberg MR, Cowan J, Broering JM, Carroll PR. High-risk prostate cancer in the United States, 1990-2007. World J Urol 2008; 26:211-218.
4. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011; 364:1708-1717.
5. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367:203-213.
6. Zhu X, Albertsen PC, Andriole GL, et al. Risk-based prostate cancer screening. Eur Urol 2012; 61:652-661.
7. Moyer VA. U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157:120-134.
8. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28:1117-1123.
9. Carroll PR, Whitson JM, Cooperberg MR. Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes? J Clin Oncol 2011; 29:345-347.
10. Bastian PJ, Boorjian SA, Bossi A, et al. High-risk prostate cancer: from definition to contemporary management. Eur Urol 2012; 61:1096-1106.
11. Cooperberg MR, Vickers AJ, Broering JM, Carroll PR, for the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) Investigators. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer 2010; 116:5226-5234.
12. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. J Am Med Assoc 2005; 294:433-439.
13. Brawley OW. Trends in prostate cancer in the United States. J Natl Cancer Inst Monographs 2012; 2012:152-156.
14. Shao YH, Demissie K, Shih W, et al. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst 2009; 101:1280-1283.
15. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 2007; 178:S14-S19.
16. Schröder FH, Hugosson J, Roobol MJ, et al. Prostate cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366:981-990.
17. Andriole GL, Crawford ED, Grubb RL III, et al. Mortality results from a randomized prostate cancer screening trial. N Engl J Med 2009; 360:1310-1319.
18. Pinsky PF, Blacka A, Kramer BS, et al. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials 2010; 7:303-311.
19. Cooperberg MR, Carroll PR. Prostate-cancer screening. N Engl J Med 2009; 361:203; author reply 204-205.
20. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
21. Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61:1079-1092.
22. Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol 2011; 29:235-241.
23. Virnig BA, Baxter NN, Habermann EB, et al. A matter of race: early-versus latestage cancer diagnosis. Health Aff (Millwood) 2009; 28:160-168.
24. Carpenter WR, Howard DL, Taylor YJ, et al. Racial differences in PSA screening interval and stage at diagnosis. Cancer Causes Control 2010; 21:1071-1080.
25. Miller DC, Litwin MS, Bergman J, et al. Prostate cancer severity among low income, uninsured men. J Urol 2009; 181:579-584.
26. Porten SP, Richardson DA, Odisho AY, et al. Disproportionate presentation of high risk prostate cancer in a safety net health system. J Urol 2010; 184:1931-1936.
27. Taksler GB, Keating NL, Cutler DM. Explaining racial differences in prostate cancer mortality. Cancer 2012; 118:4280-4289.
28. Fedewa SA, Jemal A. Prostate cancer disease severity and country of origin among black men in the United States. Prostate Cancer Prostatic Dis 2013 [Epub ahead of print]. doi: 10.1038/pcan.2012.53.
29. Madersbacher S, Alcaraz A, Emberton M, et al. The influence of family history on prostate cancer risk: implications for clinical management. BJU Int 2010; 107:716-721.
30. Sun J, Na R, Hsu F-C, et al. Genetic score is an objective and better measurement of inherited risk of prostate cancer than family history. Eur Urol 2013; 63:585-587.
31. Nakagawa H, Akamatsu S, Takata R, et al. Prostate cancer genomics, biology, and risk assessment through genome-wide association studies. Cancer Sci 2012; 103:607-613.
32. Choudhury AD, Eeles R, Freedland SJ, et al. The role of genetic markers in the management of prostate cancer. Eur Urol 2012; 62:577-587.
33. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol 2013; 63:800-809.
34. Masko EM, Allott EH, Freedland SJ. The relationship between nutrition and prostate cancer: is more always better? Eur Urol 2013; 63:810-820.
35. Punnen S, Cooperberg MR, Sadetsky N, Carroll PR. Among potent men post radical prostatectomy, does the need for phosphodiesterase inhibitors have an impact on sexual bother scores? BJU Int 2012; 109:1520-1524.
36. Hamilton AS, Albertsen PC, Johnson TK, et al. Trends in the treatment of localized prostate cancer using supplemented cancer registry data. BJU Int 2011; 107:576-584.
37. Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2007 update of an American Society of Clinical Oncology Practice Guideline. J Clin Oncol 2007; 25:1596-1605.
38. Silberstein JL, Vickers AJ, Power NE, et al. Reverse stage shift at a tertiary care center: escalating risk in men undergoing radical prostatectomy. Cancer 2011; 117:4855-4860.
39. Cooperberg MR, Ramakrishna NR, Duff SB, et al. Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis. BJU Int 2013; 111:437-450.